Can't beta dose of vildagliptin for β-cell function in type 2 diabetes

Vildagliptin [Galvus], a novel dipeptidyl peptidase IV inhibitor, is effective in the treatment of type 2 diabetes mellitus, according to findings presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) [Chicago, Illinois,US; June 2007]. Positive results for the efficacy and tolerability of vildagliptin in patients with this disease were demonstrated in several studies and pooled analyses, which included comparisons with metformin, sulfonylureas and thiazolidinediones, with particular focuses on the effects of vildagliptin on β-cell function, glycaemic control and hypertension.